Complementary and Integrative Medicine in Lung Cancer: Questions and Challenges-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Complementary and Integrative Medicine in Lung Cancer: Questions and Challenges

Published:2018-09 Issue:9-10 Volume:24 Page:862-871
ISSN:1075-5535
Container-title:The Journal of Alternative and Complementary Medicine
language:en
Short-container-title:The Journal of Alternative and Complementary Medicine

Author:

Frenkel Moshe¹²,Slater Robert¹,Sapire Kenneth³,Sierpina Victor¹

Affiliation:

1. Department of Family Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas.

2. Integrative Medicine Program, Institute of Oncology Meir Medical Center, Kfar Saba, Israel.

3. Department of Anesthesia and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publisher

Mary Ann Liebert Inc

Subject

Complementary and alternative medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/acm.2018.0175

Reference87 articles.

1. Prevalence of complementary and alternative medicine use in cancer patients during treatment

2. Complementary and alternative medicine use in lung cancer patients in eight European countries

3. Use of Complementary and Alternative Medicine Therapies to Control Symptoms in Women Living With Lung Cancer

4. Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon?

5. Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Influence of Lifestyle Factors on Immunotherapy Efficacy in Cancer Patients;Handbook of Cancer and Immunology;2024

2. Cancer Prevention and Treatment Based on Lifestyles;Cancer Treatment and Research;2024

3. Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines;Integrative Medicine Research;2021-03

4. Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy;Integrative Cancer Therapies;2021-01

5. Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients;Integrative Cancer Therapies;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3